BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 2006 (First Quarter of Fiscal 2007)
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 8% year-over-year, driven by a 6% volume increase and 2% favorable foreign currency translation. International revenue grew 7%.
• Profitability Decline: Operating income decreased 31% and Net Income decreased 34%. This decline is primarily attributable to a non-deductible charge of $114.7 million for acquired in-process research and development (IPR&D) related to the TriPath Imaging acquisition.
• Segment Performance:
  • Medical: Revenues up 10%; Operating income up 10%.
  • Diagnostics: Revenues up 2%; Operating income turned negative ($-0.3 million) due to the $114.7 million IPR&D charge.
  • Biosciences: Revenues up 11%; Operating income up 14%.
• Discontinued Operations: The company sold its Blood Glucose Monitoring (BGM) product line for $20.0 million, recognizing a pre-tax gain of $15.2 million. Results are now presented as discontinued operations.
• Debt Reduction: Total debt decreased to $1.16 billion, reducing the debt-to-capitalization ratio to 21.9% from 25.8% in the prior quarter.

Guidance, Outlook, and Risks

• Acquisition Impact: The TriPath acquisition ($362 million cash) is expected to contribute to future growth in cancer diagnostics. Management anticipates R&D expenses will increase approximately 35% in fiscal 2007, with 15% attributed to IPR&D charges.
• Margin Outlook: Gross profit margin is expected to improve by approximately 70 basis points in fiscal 2007. Selling and administrative expenses are expected to increase by 10 basis points.
• Tax Rate: The effective tax rate for the quarter was 39.0% due to the non-deductible IPR&D charge. The full-year reported tax rate is expected to be approximately 29%.
• Capital Expenditures: Expected to be in the range of $600 million to $650 million for fiscal 2007.
• Risks and Contingencies:
  • Legal Proceedings: Ongoing investigations by Connecticut and Illinois Attorneys General regarding BD's participation in the Healthcare Research & Development Institute (HRDI).
  • Raw Materials: Exposure to oil-based resin costs, though management expects to mitigate impacts through margin improvements and cost reduction.
  • Regulatory: Risks related to FDA approvals, patent expirations, and healthcare cost containment initiatives.

Investor Verification Checklist

• TriPath Integration: Verify the timeline for commercialization of the three acquired IPR&D projects (molecular/Pap test, breast staging, ovarian cancer detection) and their impact on future R&D expenses.
• BGM Divestiture: Confirm the final accounting treatment of the BGM sale and ensure no residual liabilities remain from the exit costs.
• Flu Test Performance: Monitor the market acceptance of the internally-sourced flu test in Japan, which contributed to a revenue decline in the Diagnostics segment.
• Legal Exposure: Track the status of the HRDI investigations to assess potential future accruals or fines.
• Debt Covenants: Verify continued compliance with the interest expense coverage ratio covenant (minimum 5-to-1) under the amended credit facility.